New York-based One Drop published outcomes from a retrospective cohort study in the Journal of Medical Internet Research (JMIR). The study focused on indicators of glycemic control and health data logging in adults with type 2 diabetes using the One Drop digital health platform.
According to a news release, cohort members using One Drop’s glucose forecasting feature were more likely to log glucose values in the app than those who did not receive forecasts. They also had more glucose measurements within a healthy range after 12 weeks.
Researchers identified glucose logging as a partial mediator of the relationship between forecast exposure and week-12 average glucose, highlighting a potential mechanism through which glucose forecasts impact those with type 2 diabetes, improving engagement associated with self-monitoring of blood glucose and better glycemic management, One Drop said.
“AI-based digital health tools must go beyond data generation to keep people engaged and motivated to make healthier decisions,” Dr. Dan Goldner, EVP of advanced technologies, research, and discovery at One Drop, said in the release. “Results from the present study validate the strength of our predictive intelligence and cross-disciplinary approach: behavioral data science. In simple terms, One Drop AI reduces cognitive burden caused by managing a chronic condition like diabetes and encourages self-care behaviors to drive cost-saving outcomes.”
One Drop’s platform uses AI to provide direct support through eight-hour glucose forecasts with better than 90% accuracy and immediate insights delivered to users. The company said this feature simplifies healthy decision-making by connecting everyday behaviors with outcomes and offering ongoing guidance to complement the support members receive from healthcare providers.
To date, the company has aggregated more than 39 billion longitudinal health data points from approximately 1.5 million members worldwide. The eight-hour glucose forecasts and its blood pressure insights have CE mark approval in Europe.
One Drop said it is developing a minimally invasive health sensor with continuous glucose monitoring (CGM) capabilities designed for greater flexibility and insights for people with diabetes compared to blood glucose monitor (BGM) fingersticks. That platform is pending regulatory approval and commercial adoption.
